About company
Qyuns is developing six candidates, most of them interleukin antibodies. It has two biosimilar drugs in China clinical trials, including a biosimilar to tocilizumab, a Chugai drug marketed as Actemra for various rheumatoid arthritis conditions.
- Unknown
- Unknown
- Unknown
- www.qyuns.net/en/index.aspx
- Not verified company
